The partners will use a $5M NCI grant to add seven biomarkers to an EGFR electrochemical assay for non-small-cell lung-carcinoma.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.
Some researchers believe that the use of microfluidics in the analysis of exosomes will help clinicians overcome the problem of heterogeneity in cancer cells.
The technology uses a conducting polymer-based electrochemical chip with an array of electrodes and employs an electrical field to release and detect mutations.
Hong Kong-based Rainbow Genomics will provide exome sequencing while UCLA will interpret the data and deliver a clinical report.
Through its large network of ambulatory labs, the university's pathology and lab medicine department is evaluating a BioFire rapid diagnostic test for the flu.
Investigators concluded that wearables show early promise in some cases, but there's limited evidence to substantiate claims of their ability to improve outcomes.
The initiative's four research projects will use use genetic and other technologies to detect and treat cancer at its earliest stages.